Patents Assigned to TECHNOPHAGE, INVESTIGAÇÃO E DESENVOLVIMENTO EM BIOTECNOLOGIA, SA
-
Publication number: 20210187046Abstract: The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections, in particular respiratory bacterial infections such as bacterial pneumonia. More specifically, the present invention is directed to novel bacteriophage strains and cocktails thereof, as well as variants thereof; and methods of using same in the treatment and prevention of bacterial infections, including respiratory infections caused by, e.g., Pseudomonas aeruginosa and/or Klebsiella pneumoniae. The cocktails are used as pharmaceutical compositions either alone or in further combination with other therapies, e.g., antibiotics or other standard and non-standard therapies for respiratory infections.Type: ApplicationFiled: December 18, 2020Publication date: June 24, 2021Applicants: TECHNOPHAGE, INVESTIGAÇÃO E DESENVOLVIMENTO EM BIOTECNOLOGIA, SA, TECNIFAR - INDUSTRIA TECNICA FARMACEUTICA, S.A.Inventors: Clara Isabel Rodrigues Leandro, Ana Raquel Martins Barbosa, Daniela Jones Dias, Ana Filipa Martins, Miguel Ângelo da Costa Garcia, Sofia Volker Côrte-Real
-
Antibody molecules and peptide delivery systems for use in alzheimer's disease and related disorders
Patent number: 10654917Abstract: The present invention relates to antibody molecules and peptide delivery systems for use in the treatment and management of Alzheimer's disease and related disorders. In particular, the antibody molecules preferentially bind oligomeric forms of beta-amyloid peptide, in single domain format, and the peptide delivery systems facilitate specific transport of such antibody molecules, as well as other cargo molecules, across the blood-brain barrier. The invention also relates to constructs of the antibody molecules and the delivery peptides, as well as pharmaceutical compositions comprising effective amounts of the antibody molecules, delivery peptides, and/or their constructs, including humanized versions of the antibody molecules and constructs.Type: GrantFiled: January 29, 2016Date of Patent: May 19, 2020Assignee: TECHNOPHAGE, INVESTIGACAO E DESENVOLVIMENTO EM BIOTECNOLOGIA, SAInventors: Sofia Volker Côrte-Real, Vera Luísa Santos Neves, Pedro Manuel Correia Canhão, Tiago Fleming Outeiro, Miguel Augusto Rico Botas Castanho, Frederico Nuno Castanheira Aires Da Silva, Soraia Rafaela Santiago De Oliveira -
Patent number: 10280211Abstract: The present invention relates to methods for screening and producing polypeptides that immunospecifically bind to an antigen, which: polypeptides comprise binding domains that are derived from rabbit immunoglobulin. Using rabbit antibody heavy-chain or light-chain scaffolds, the methods of the invention allow identification of novel CDR loops and framework regions that confer enhanced stability and/or affinity to isolated immunoglobulin variable domains, in particular, relative to those derived from rodent antibodies. The enhanced stability and/or affinity of the variable domains of the invention permit their use in the production research tools or therapeutic immunospecific polypeptides, including single domain immunospecific polypeptides, i.e., comprising one of a VH or VL domain.Type: GrantFiled: April 30, 2008Date of Patent: May 7, 2019Assignee: TECHNOPHAGE, INVESTIGAÇÃO E DESENVOLVIMENTO EM BIOTECNOLOGIA, SAInventors: João Manuel Braz Goncalves, Frederico Nuno Castanheira Aires Da Silva
-
Patent number: 9962419Abstract: The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections, in particular diabetic foot infections. More specifically, the present invention is directed to novel cocktails of bacteriophage strains F44/10, F1 25/10, F770/05, F510/08, F1 245/05, and/or variants thereof; and methods of using same in the treatment and prevention of bacterial infections, including cutaneous ulcers associated with diabetic foot infections, caused by, e.g., Staphylococcus aureus, Pseudomonas aeruginosa, and/or Acinetobacter baumannii. The cocktails are used as pharmaceutical compositions either alone or in further combination with other therapies, e.g., antibiotics, growth factors, or other standard, as well as non-standard, therapies for diabetic foot infections.Type: GrantFiled: March 19, 2013Date of Patent: May 8, 2018Assignee: Tecnifar—Industria Tecnica Farmaceutica, S.A. Technophage, Investigação E Desenvolvimento Em Biotecnologia, SAInventors: João João Duarte Alves Mendes, Clara Isabel Rodrigues Leandro, Sofia Volker Côrte-Real
-
Patent number: 9737579Abstract: The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophage F387/08, F391/08, F394/08, F488/08, F510/08, F44/10, and F125/10, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophage and/or isolated polypeptides, as well as to methods for the treatment and prevention of bacterial infections using same, either alone or in combination with other antibacterial therapies, e.g., antibiotics and/or other phage therapies.Type: GrantFiled: July 22, 2016Date of Patent: August 22, 2017Assignees: Technophage, Investigacao E Desenvolvimento Em Biotecnologia, SA, Tecnifar—Industria Tecnica Farmaceutica, S.A.Inventors: Miguel Ângelo Da Costa Garcia, Carlos Jorge Sousa De São José, Clara Isabel Rodrigues Leandro, Filipa Maria Rodrigues Pardal Dias Antunes Marçal Da Silva, Ana Raquel Martins Barbosa
-
Patent number: 9487773Abstract: The invention relates to cell-based methods for diversifying, expressing and selecting binding molecules, e.g., antibodies, and target molecules to which they bind, all of which are expressed in the same cell. The target molecule can be a member of a ligand binding pair comprising a cell-surface expressed ligand binding receptor molecule and its cognate ligand, which interact within the cell. The methods provide retaining either the antibody or its target in a cell organelle as the site of binding and interaction. By performance of the methods, the binding or non-binding of the antibody to its target molecule within the cell produces a cell phenotype that is detectable at the cell surface via high throughput assays, e.g., flow cytometry. The methods are particularly useful for generating, recovering and providing antibodies that have optimal target molecule binding properties or activities for potential therapeutic use. Methods for generating diversity in such antibodies are also provided.Type: GrantFiled: February 28, 2014Date of Patent: November 8, 2016Assignee: TECHNOPHAGE, INVESTIGACAO E DESENVOLVIMENTO EM BIOTECNOLOGIA, SAInventors: João Manuel Braz Gonçalves, Frederico Nuno Castanheira Aires da Silva, Sofia Volker Côrte-Real, Soraia Rafaela Santiago de Oliveira
-
Patent number: 9399678Abstract: The present invention relates to polypeptides comprising one or more antibody single domains, or antigen-binding fragments thereof, directed against Tumor Necrosis Factor-alpha, in particular, two light chain variable domains in dimeric form, where the dimer has high solubility. It also relates to methods of using anti-Tumor Necrosis Factor-alpha polypeptides in treating inflammatory disorders, including rheumatoid arthritis. Compositions and methods for enhancing therapeutic potential of anti-Tumor Necrosis Factor-alpha polypeptides are provided, including linking the polypeptide to an albumin-binding domain and/or de-immunizing the polypeptide, to provide therapeutic agents with good solubility, enhanced serum half-life, and/or reduced immunogenicity, while substantially maintaining the specific binding properties of the anti-Tumor Necrosis Factor-alpha polypeptides.Type: GrantFiled: September 19, 2012Date of Patent: July 26, 2016Assignee: Technophage, Investigacao E Desenvolvimento Em Biotecnologia, SAInventors: Frederico Nuno Castanheira Aires da Silva, Sofia Volker Cörte-Real, Rui Pedro da Silva Albuquerque e Freitas, Sara Ferreira Llorente Grancho Lourenço
-
Patent number: 9399049Abstract: The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophage F387/08, F391/08, F394/08, F488/08, F510/08, F44/10, and F125/10, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophage and/or isolated polypeptides, as well as to methods for the treatment and prevention of bacterial infections using same, either alone or in combination with other antibacterial therapies, e.g., antibiotics and/or other phage therapies.Type: GrantFiled: November 17, 2015Date of Patent: July 26, 2016Assignees: Technophage, Investigacao E Desenvolvimento Em Biotecnologia, SA, Tecnifar-Industria Tecnica Farmaceutica, S.A.Inventors: Miguel Ângelo Da Costa Garcia, Carlos Jorge Sousa De São José, Clara Isabel Rodrigues Leandro, Filipa Maria Rodrigues Pardal Dias Antunes Marçal Da Silva, Ana Raquel Martins Barbosa
-
Patent number: 9134312Abstract: The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.Type: GrantFiled: February 5, 2010Date of Patent: September 15, 2015Assignees: Tecnifar—Industria Tecnica Farmaceutica, S.A., Technophage, Investigação E Desenvolvimento Em Biotecnologia, SAInventors: Miguel Ängelo Da Costa Garcia, Carlos Jorge Sousa De São José, Clara Isabel Rodrigues Leandro, Filipa Maria Rodrigues Pardal Dias Antunes Marçal Da Silva, Sara Ferreira Llorente Grancho Lourenço
-
Publication number: 20150044208Abstract: The present invention relates to compositions and methods comprising a modified albumin-binding domain to improve the pharmacokinetic properties of therapeutic molecules. The modified peptides show reduced immunogenicity and/or proved solubility. In particular, compositions and methods for enhancing therapeutic potential of protein therapeutics are provided including linking a protein albumin-binding domain, which has been modified to reduce immunogenicity and/or improve solubility, to a therapeutic protein, including therapeutic antibodies, antibody fragments, antibody single domains and/or dimers of antibody single domains. These linked polypeptides can exhibit enhanced serum half life without exacerbated immunogenicity and/or without decreased solubility, and without substantially affecting the specific binding properties of the therapeutic protein.Type: ApplicationFiled: September 19, 2012Publication date: February 12, 2015Applicant: TECHNOPHAGE, INVESTIGAÇÄO E DESENVOLVIMENTO EM BIOTECNOLOGIA, SAInventors: Frederico Nuno Castanheira Aires da Silva, Sofia Volker Côrte-Real, Sara Ferreira Llorente Grancho Lourenço
-
Publication number: 20140249044Abstract: The invention relates to cell-based methods for diversifying, expressing and selecting binding molecules, e.g., antibodies, and target molecules to which they bind, all of which are expressed in the same cell. The target molecule can be a member of a ligand binding pair comprising a cell-surface expressed ligand binding receptor molecule and its cognate ligand, which interact within the cell. The methods provide retaining either the antibody or its target in a cell organelle as the site of binding and interaction. By performance of the methods, the binding or non-binding of the antibody to its target molecule within the cell produces a cell phenotype that is detectable at the cell surface via high throughput assays, e.g., flow cytometry. The methods are particularly useful for generating, recovering and providing antibodies that have optimal target molecule binding properties or activities for potential therapeutic use. Methods for generating diversity in such antibodies are also provided.Type: ApplicationFiled: February 28, 2014Publication date: September 4, 2014Applicant: Technophage, Investigaçâo E Desenvolvimento Em Biotecnologia, SAInventors: João Manuel Braz Gonçalves, Frederico Nuno Castanheira Aires da Silva, Sofia Volker Côrte-Real, Soraia Rafaela Santiago de Oliveira
-
Publication number: 20140079671Abstract: The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophage F387/08, F391/08, F394/08, F488/08, F510/08, F44/10, and F125/10, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophage and/or isolated polypeptides, as well as to methods for the treatment and prevention of bacterial infections using same, either alone or in combination with other antibacterial therapies, e.g., antibiotics and/or other phage therapies.Type: ApplicationFiled: September 19, 2011Publication date: March 20, 2014Applicants: TECHNOPHAGE, INVESTIGAÇÃO E DESENVOLVIMENTO EM BIOTECNOLOGIA, SA, TECNIFAR-INDÚSTRIA TÉCNICA FARMACÊUTICA, S.A.Inventors: Miguel Ângelo Da Costa Garcia, Carlos Jorge Sousa De São José, Clara Isabel Rodrigues Leandro, Filipa Maria Rodrigues Pardal Dias Antunes Marçal Da Silva, Ana Raquel Martins Barbosa
-
Publication number: 20120052048Abstract: The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.Type: ApplicationFiled: February 5, 2010Publication date: March 1, 2012Applicants: TECNIFAR-INDUSTRIA TECNICA FARMACEUTICA, S.A., TECHNOPHAGE INVESTIGACAO E DESENVOLVIMENTO EM BIOTECNOLOGIA SAInventors: Miguel Ängelo Da Costa Garcia, Carlos Jorge Sousa De São José, Clara Isabel Rodrigues Leandro, Filipa Maria Rodrigues Pardal Dias Antunes Marçal Da Silva, Sara Ferreira Llorente Grancho Lourenço